<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00748345</url>
  </required_header>
  <id_info>
    <org_study_id>P070601</org_study_id>
    <nct_id>NCT00748345</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics of Caspofungin in Burn Patients</brief_title>
  <acronym>Caspo-brûlés</acronym>
  <official_title>Pharmacokinetics of Caspofungin in Burn Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Drug pharmacokinetics of antimicrobial agents is significantly altered in the burn patients.
      Additionally, burn patient population exhibits a wide inter- and intrapatient variation in
      drug handling. Several investigations carried out in burn patients treated with e.g.
      fluconazole showed the requirement to increase daily dose in comparison with healthy
      volunteers. However, no pharmacokinetic data are available of caspofungin in the burn
      population. The aim of this investigation is to investigate pharmacokinetics of caspofungin
      in burn patients after a single usual dose (70 mg i.v.), in order to determine the optimal
      dose in this population.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of this investigation is to investigate pharmacokinetics of caspofungin in burn
      patients after a single usual dose (70 mg i.v.). Blood samples are drawn just before
      administration and 0.25, 0.5,1 1.5, 3, 6, 12, 24, 48, 72, 96 and 120 hours after
      administration. Caspofungin plasma concentrations are measured by liquid-chromatography
      spectrometry mass tandem.The primary end-points are :

        -  area under the curve of caspofungin plasma concentrations over 24 hours

        -  mean peak level and trough concentration (24 hours after dosing)

      The secondary end-points are :

        -  mean total clearance

        -  mean distribution volume These parameters will be compared to those usually observed in
           non burn patients. The optimal dose in burn patients is the dose achieving an exposure
           similar to that in non burn patients.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2009</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">February 2010</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>area under the curve of caspofungin plasma concentrations over 24 hours mean peak level and trough concentration (24 hours after dosing)</measure>
    <time_frame>18 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>mean total clearance</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mean distribution volume</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">2</enrollment>
  <condition>Thermal Injury</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Caspofungin (drug)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Caspofungin (drug)</intervention_name>
    <description>pharmacokinetics of caspofungin in burn patients after a single usual dose (70 mg i.v.), in order to determine the optimal dose in this population</description>
    <arm_group_label>1</arm_group_label>
    <other_name>pharmacokinetics of caspofungin in burn patients</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 - 60 years old

          -  burn surface : 20-60% total body surface area

          -  delay of injury time : 8-15 days

          -  lack of fungal infection

          -  delay of hospitalization : &gt; 5 days

          -  written informed consent

          -  last biological picture in 24 hours before inclusion

        Exclusion Criteria:

          -  survival inferior to 5 days

          -  surgical intervention planned in the next five days following inclusion

          -  moderate or severe hepatic impairment according to Child Plug B &gt; 9

          -  pregnancy

          -  allergy to caspofungin or excipients (saccharose, mannitol and frozen acetic acid)

          -  patient already included in other study

          -  concomitant administration of CYP450 inducers : rifampicin, efavirenz, phenobarbital,
             phenytoin, carbamazepine

          -  withdrawal of consent

          -  event (during the first 48 hours following administration) susceptible to modify
             pharmacokinetic parameters

          -  Investigator decision

          -  no social security insurance
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christophe Vinsonneau, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cochin</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 31, 2008</study_first_submitted>
  <study_first_submitted_qc>September 5, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 8, 2008</study_first_posted>
  <last_update_submitted>December 15, 2011</last_update_submitted>
  <last_update_submitted_qc>December 15, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 16, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Caspofungin,</keyword>
  <keyword>burn patients,</keyword>
  <keyword>pharmacokinetics,</keyword>
  <keyword>optimal dose,</keyword>
  <keyword>antifungal treatment</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Caspofungin</mesh_term>
    <mesh_term>Echinocandins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

